Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Barclays Global Consumer Staples Conference 2025
27 slides from Prestige Consumer Healthcare's conference presentation, Sep 4, 2025
Slide 1: Barclays Global Consumer Staples Conference
September 4, 2025 Barclays Global Consumer Staples Conference
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, diluted EPS, and f
Slide 3: Contents Overview
Contents Overview I. Introduction to Prestige Consumer Healthcare II. Brand-Building Playbook III. Financial Strategy & Capital Allocation IV. The Road Ahead 2025 BARCLAYS GLOBAL CONSUMER STAPLES CONFERENCE 3
Slide 4: I. Introduction to Prestige Consumer Healthcare
I. Introduction to Prestige Consumer Healthcare 2 20 02 25 5B BA AR RC CL LA AY YS SGGL LOOB BA AL LC COON NS SU UMME ER RS ST TA AP PL LE ES SC COON NF FE ER RE EN NC CE E
Slide 5: Who We Are: Helping Consumers Care for Themselves
Who We Are: Helping Consumers Care for Themselves eye drops per year throat drops for every cold season doses of pain relief per week infections treated annually 2025 BARCLAYS GLOBAL CONSUMER STAPLES CONFERENCE 5
Slide 6: Diversified Portfolio of Leading Consumer Healthcare Brands
Diversified Portfolio of Leading Consumer Healthcare Brands Total Sales by Category Diverse Portfolio of Market-Leading Brands Oral Motion Sickness Care Other Constipation Cough & Cold 9% 1% Rehydration GI 9% Feminine Hygiene Analgesics 23% Vaginal Anti-Fungal 10% Allergy & Redness Relief Dry Eye Re
Slide 7: Proven Strategy Delivers Long-Term Performance
Proven Strategy Delivers Long-Term Performance Proven Ability to Execute Value Creation Strategy 1 Investing for Growth with Proven Brand-Building Playbook 2 Superior Business Attributes Drive Strong Free Cash Flow 3 Scalable & Efficient Platform Enables Capital Allocation Optionality +3.4% +2.4% +8
Slide 8: II. Brand-Building Playbook
II. Brand-Building Playbook 2 20 02 25 5B BA AR RC CL LA AY YS SGGL LOOB BA AL LC COON NS SU UMME ER RS ST TA AP PL LE ES SC COON NF FE ER RE EN NC CE E
Slide 9: Brand-Building Focus Positions Us for Long-Term Growth
Brand-Building Focus Positions Us for Long-Term Growth 1 Understanding Consumer Insights and Opportunity 2 Flexible & Agile Brand Strategies in a Dynamic Environment 3 Expanding Consumer Reach and Growth Through E-Commerce Expansion 4 Consumer-Driven New Product Development Resulting Long-Term Succe
Slide 10: Dramamine: Thinking Beyond Motion Sickness
Dramamine: Thinking Beyond Motion Sickness Broadened Motion Sickness Offering Expanding an Iconic Brand into Nausea & Beyond Robust Digital Campaigns Supporting Brand 2011 New Forms & Flavors #1 Brand* in Motion Sickness Leading brand* in Nausea/Motion Sickness Successful Brand-building Resulting in
Slide 11: Portfolio Diversity Enables Agile Marketing Strategy
Portfolio Diversity Enables Agile Marketing Strategy Agility in Action ... ... Supported by Brand-Building Playbook Engaging Campaigns Insight Driven Innovation ~11% & Content ~8% Impactful claims FY 25 Category Growth* Expanded consumer Limited FY 25 Clear Eyes marketing need states opportunities d
Slide 12: Continue to Drive Strong E-Commerce Growth
Continue to Drive Strong E-Commerce Growth E-Commerce as a % of Net Sales* ~16% Engaging ~14% +4x ~11% Content Driving Traffic ~4% & Conversion FY 19 FY 21 FY 23 FY 25 Continued strong performance across E-Commerce business in FY ‘25 Continually Upgrading User Experience *MULO+ Retail sales data and
Slide 13: Innovation Playbook Wide-Ranging to Address Consumer Needs
Innovation Playbook Wide-Ranging to Address Consumer Needs Product Development Initiatives Extend Brand Through Better Consumer Experience or Claims Innovate Through Technology or Forms New Categories Pediatric Mental Oral Stool Expansion Nausea Alertness Softener 2025 BARCLAYS GLOBAL CONSUMER STAPL
Slide 14: Attractive International Business
Attractive International Business Broad Geographic Reach Growing International Presence Proven Revenue Growth Playbook % Int’l Revenue* Key Brands Australia 50%+ Broad ~16% Innovation 55% 14% Digital & Asia Retail 10% Marketing 20% ◼ Strategic collaboration with Europe Strategic long-term broker par
Slide 15: III. Financial Strategy & Capital Allocation
III. Financial Strategy & Capital Allocation 2 20 02 25 5B BA AR RC CL LA AY YS SGGL LOOB BA AL LC COON NS SU UMME ER RS ST TA AP PL LE ES SC COON NF FE ER RE EN NC CE E
Slide 16: Robust Free Cash Flow Supports Value-Enhancing Capital Allocation
Robust Free Cash Flow Supports Value-Enhancing Capital Allocation Adj. FY Free Cash Flow(2) & Net Leverage(3) Capital Allocation Highlights Significant debt reduction to 2.4x Net Leverage(3) $254 $239 $243 $222 $213 $52 million in share repurchases in FY25 4.2x Building cash balance in advance of fu
Slide 17: Disciplined Capital Allocation Priorities Unchanged
Disciplined Capital Allocation Priorities Unchanged Organic Long-Term Algorithm… 1 Invest in Current Brands to Drive Organic Growth 2 Pursue M&A That is Attractive to Shareholders Ample Capacity to Pursue Brands & Portfolios of Scale Anticipate approximately $1 billion total Free Cash Flow(2) over t
Slide 18: M&A: Significant Capacity Supports Continued Opportunity
M&A: Significant Capacity Supports Continued Opportunity Consumer Healthcare is Fragmented Plentiful M&A Debt Capacity* Other U.S. OTC Market Share Net Fragmentation Creates 2.4x Leverage(3) Opportunity1 27% Average Market Share of Top 3 CH Brands Global Consumer Healthcare Categories are Less vs. $
Slide 19: IV. The Road Ahead
IV. The Road Ahead 2 20 02 25 5B BA AR RC CL LA AY YS SGGL LOOB BA AL LC COON NS SU UMME ER RS ST TA AP PL LE ES SC COON NF FE ER RE EN NC CE E
Slide 20: FY 26 Outlook
FY 26 Outlook ◼ Expected revenue decline due largely to eye care supply constraints in first half ◼ Continue to benefit from well-diversified portfolio and brand-building playbook ◼ Revenues of $1,100 to $1,115 million Top Line Trends — Expected organic revenue down approximately (1.5%) to (3.0%) —
Slide 21: Robust Long-term Growth Algorithm Unchanged
Robust Long-term Growth Algorithm Unchanged Organic Long-Term Algorithm High Proven & Organic Growth(1) Free Cash Flow(2) Repeatable M&A of 2.0% to 3.0% Generation Strategy Current Leverage Supports Additional 6.0% to 8.0% EPS Growth Upside Potential Value Creating Capital Allocation Optionality Pro
Slide 22: Portfolio & Strategy Well-Positioned for Long-Term Value Creation
Portfolio & Strategy Well-Positioned for Long-Term Value Creation 1 Diversified Portfolio of Leading, Trusted Brands 2 Established Organic Growth Brand-Building Playbook 3 Superior Financial Profile Generating Consistent Free Cash Flow 4 Scalable Platform 5 Organic Growth Reinforced by Proven & Repe
Slide 23: Appendix / Q&A
Appendix / Q&A 2025 BARCLAYS GLOBAL CONSUMER STAPLES CONFERENCE
Slide 24: Appendix
Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measures in the attached Reconciliation Schedules and / or our earnings release dated May 8, 2025 in the “About Non-GAAP Financial Measures” section. (2) EBITDA & EBITDA Margin,
Slide 25: Reconciliation Schedules
Reconciliation Schedules Organic Revenue Year Ended March 31, 2025 2020 (In Millions) GAAP Total Revenues $ 1,137.8 $ 963.1 Revenue Change CAGR 3.4% Adjustments: Impact of foreign currency exchange rates (0.1%) Impact of acquisitions & divestitures(a) (0.9%) Total Adjustments (1.0%) Non-GAAP Organic
Slide 26: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted Net Income & Adjusted EPS Year Ended March 31, 2025 2020 Adjusted Adjusted Net Income EPS Net Income EPS (In Thousands, except per share data) GAAP Net Income (Loss) and Diluted EPS $ 214,605 $ 4.29 $ 142,281 $ 2.78 Adjustments: Transition & other costs
Slide 27: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted Free Cash Flow 2021 2022 2023 2024 2025 (In Thousands) GAAP Net Income $ 164,682 $ 205,381 $ (82,306) $ 209,339 $ 214,605 Adjustments Adjustments to reconcile net income (loss) to net cash provided by operating activities as shown in the Statement of Cas
Prestige Consumer Healthcare — Barclays Global Consumer Staples Conference 2025 on 6ix